Is Reata Pharmaceuticals, Inc. (RETA) a Buy, Sell, or Hold?
Reata Pharmaceuticals, Inc.
NASDAQ:RETA
$172.36 USD
$0.04 (0.02%)
- Volume
- 1.91M
- Average Volume
- 969.32K
- Market Capitalization
- $6.57B
- P/E Ratio
- -20.07
- Dividend Yield
- 0.00%
- Price Target
- $46.00
- Year High
- $172.46
- Year Low
- $21.83
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.75
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | J. Warren Huff |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | RETA |
| CUSIP | 75615P103 |
| CIK | 0001358762 |
| Web | https://www.reatapharma.com |
| Phone | 972 865 2219 |
| Currency | USD |
| Employees | 321 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -1.82 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.75 |
| Quick Ratio | 6.75 |
| Cash Ratio | 0.72 |
Sales & Book Value
| Annual Sales | $2.22M |
| Price / Sales | 2963.20 |
| Cash Flow | -5.71 |
| Price / Cash Flow | -31.64 |
| Price / Book | -95.29 |
Price Target and Rating
| Average Stock Price Forecast | $46.00 |
| High Stock Price Forecast | $115.00 |
| Low Stock Price Forecast | $27.00 |
| Forecast Upside/Downside | 274.70% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-8.59 |
| Trailing P/E Ratio | -20.07 |
| PEG Ratio | -0.38 |
| P/E Growth | -0.38 |
| Net Income | $-311.9M |
| Net Margin | -14074.95% |
| Pretax Margin | -14076.08% |
| Return on Equity | 47.21% |
| Return on Assets | -60.62% |
Financials Score
| AltmanZ Score | 5.37 |
| Piotroski Score | 2.00 |
| Working Capital | 276.76M |
| Total Assets | 502.59M |
| Ebit | -103.29M |
| Market Cap | 6.57B |
| Total Liabilities | 415.3M |
Poll Results
About Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Stock
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for individuals afflicted with severe or life-threatening illnesses. A key focus is bardoxolone methyl (often referred to as bardoxolone), which is currently undergoing Phase 3 clinical trials for two distinct conditions: chronic kidney disease (CKD) associated with Alport syndrome, and a specific type of pulmonary arterial hypertension linked to connective tissue diseases. Bardoxolone also has an offering for autosomal dominant polycystic kidney disease (ADPKD). The pipeline further includes omaveloxolone, currently in Phase II development for Friedreich's ataxia. Reata is also advancing Phase 2 studies for various other chronic kidney di ... seases, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, and focal segmental glomerulosclerosis, among others. Beyond these, the company's earlier-stage development includes RTA 901, aimed at neurological disorders, and RTA 1701, which holds potential for treating a spectrum of autoimmune, inflammatory, and fibrotic conditions. The company has established strategic partnerships, including an agreement with Kyowa Kirin Co., Ltd. for the development and commercialization of bardoxolone across various renal, cardiovascular, diabetes, and metabolic indications within a broad territory spanning Japan, China, Hong Kong, Macao, South Korea, Taiwan, and several Southeast Asian nations (Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia). Additionally, Reata collaborates with AbbVie Inc. to jointly research, develop, and commercialize second- and later-generation Nrf2 activators for all indications excluding renal, cardiovascular, and metabolic applications. Originally incorporated in 2002 as Reata Discovery, Inc., the company officially became Reata Pharmaceuticals, Inc. in May 2005. It is headquartered in Plano, Texas.
Frequently Asked Questions
-
What is the current Reata Pharmaceuticals, Inc. (RETA) stock price?
-
Reata Pharmaceuticals, Inc.(NASDAQ:RETA) stock price is $172.36 in the last trading session. During the trading session, RETA stock reached the peak price of $172.46 while $21.83 was the lowest point it dropped to. The percentage change in RETA stock occurred in the recent session was 0.02% while the dollar amount for the price change in RETA stock was $0.04.
-
RETA's industry and sector of operation?
-
The NASDAQ listed RETA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RETA?
-
J. Warren Huff | Chairman, Chief Executive Officer & Sec.
Michael D. Wortley | Executive Vice President and Chief Legal & Compliance Officer
|
|
| -
How many employees does RETA have?
-
Number of RETA employees currently stands at 321. RETA operates from 5320 Legacy Drive, Plano, TX 75024, US.
-
Link for RETA official website?
-
Official Website of RETA is: https://www.reatapharma.com
-
How do I contact RETA?
-
RETA could be contacted at phone #972 865 2219 and can also be accessed through its website. RETA operates from 5320 Legacy Drive, Plano, TX 75024, US.
-
How many shares of RETA are traded daily?
-
The average number of RETA shares traded daily for last 3 months was 969.32K.
-
What is the market cap of RETA currently?
-
The market value of RETA currently stands at $6.57B with its latest stock price at $172.36